Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 20:9:281.
doi: 10.12688/wellcomeopenres.21403.1. eCollection 2024.

A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial)

Kathryn Maitland  1   2 , Nchafasto Obonyo  2 , Mainga Hamaluba  2 , Emmanuel Ogoda  2 , Christabel Mogaka  2 , Thomas N Williams  1   2 , Charles Newton  2   3 , Symon M Kariuki  2   4 , Diana M Gibb  5 , A Sarah Walker  5 , Roisin Connon  5 , Elizabeth C George  5
Affiliations

A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial)

Kathryn Maitland et al. Wellcome Open Res. .

Abstract

Background: African children with cerebral malaria and seizures caused Plasmodium falciparum are at greater risk of poor outcomes including death and neurological sequelae. The agonal events are severe hypoventilation and respiratory arrest often triggered by seizures. We hypothesised that prophylactic anti-seizure medication (ASM) could avert 'spikes' of intracranial pressure during or following seizures and that adequate ventilation could be supported by biphasic Cuirass Ventilation (BCV) which requires no intubation.

Methods: A Phase I trial conducted in Kilifi, Kenya designed to provide data on safety, feasibility and preliminary data on seizure control using prophylactic ASM (levetiracetam) and BCV as non-invasive ventilatory support in children with cerebral malaria. Children aged 3 months to 12-years hospitalised with P falciparum malaria (positive rapid diagnostic test or a malaria slide), a Blantyre Coma Score ≤2 and a history of acute seizures in this illness are eligible for the trial. In a phased evaluation we will study i) BCV alone for respiratory support (n=10); ii) prophylactic LVT: 40mg/kg loading dose then 30mg/kg every 12 hours given via nasogastric tube for 72 hours (or until fully conscious) plus BCV support (n=10) and; iii) prophylactic LVT: 60mg/kg loading dose then 45mg/kg every 12 hours given via nasogastric tube for 72 hours (or until fully conscious) plus BCV support (n=10). Primary outcome measure: cumulative time with a clinically detected seizures or number of observed seizures over 36 hours. Secondary outcomes will be assessed by feasibility or ability to implement BCV, and recovery from coma within 36 hours. Safety endpoints include: aspiration during admission; death at 28 days and 180 days; and de-novo neurological impairments at 180 days.

Conclusions: This is a Phase I trial largely designed to test the feasibility, tolerability and safety of using non-invasive ventilatory support and LVT prophylaxis in cerebral malaria.

Registration: ISRCTN76942974 (5.02.2019); PACTR202112749708968 (20.12.2021).

Keywords: Africa; biphasic cuirass ventilationn; children; clinical trial; levetiracetam; non invasive ventilation; prophylactic anticonvulsants; severe malaria.

Plain language summary

Unfortunately, children with cerebral malaria continue to have very poor outcomes including severe hypoventilation and respiratory arrest (i.e. breathing is too slow or stops) during hospitalization which is often triggered by seizures. We will explore the potential benefits of a special type of ventilation that applies suction or negative pressure to the chest (meaning keeping children breathing by pushing air in and out of their lungs) in combination with anticonvulsants given before children have had any fits We will use a device called biphasic Cuirass Ventilation (BCV) that can be used by non-specialists to help children breath. BCV applies both negative and positive pressure to the chest, covering both inspiration (breathing in) and expiration (breathing out) phases of breathing, which is more appropriate for periods of when the breathing is too slow or stops for a period of time. We will also use an anticonvulsant drug, called levetiracetam to prevent seizures. It has been safely used in Malawian children and shown to improve outcomes. This will be given directly into the stomach via a nasogastric tube (tubes down the nose into the stomach) The study will be carried out at Kilifi County Hospital, Kenya and plans to enrol 30 children aged 3 months to 12 years with cerebral malaria and a positive malaria test The first ten children with have the BCV device only to assist respiration until they recover from their coma. The next twenty children in the trial will have the BCV device in addition with anticonvulsants given before children have had any fits as a preventive strategy to stop fits. All children will have regular monitoring during the period of coma/ventilation and will be followed up on days 28 and 180. The study aims to generate feasibility and safety data to support future trials.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

References

    1. Dondorp AM, Fanello CI, Hendriksen IC, et al. : Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647–57. 10.1016/S0140-6736(10)61924-1 - DOI - PMC - PubMed
    1. Carter JA, Mung'ala-Odera V, Neville BG, et al. : Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatry. 2005;76(4):476–81. 10.1136/jnnp.2004.043893 - DOI - PMC - PubMed
    1. Molyneux ME, Taylor TE, Wirima JJ, et al. : Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med. 1989;71(265):441–59. 10.1093/oxfordjournals.qjmed.a068338 - DOI - PubMed
    1. Newton CR, Chokwe T, Schellenberg JA, et al. : Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg. 1997;91(2):161–5. 10.1016/s0035-9203(97)90207-8 - DOI - PubMed
    1. Molyneux ME: Malaria--clinical features in children. J R Soc Med. 1989;82 Suppl 17(Suppl 17):35–8. - PMC - PubMed

LinkOut - more resources